Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1937)	3/24/2002 8:07:56 PM
From: arnie h	Read Replies (2) \| Respond to of 10345

<What would Merck or Novartis (merely blind examples/picks) pay for it, in your opinion?> I'm still focused on the $8 Bil paid by Bristol for the DuPont pharmaceutical business. Same level of current sales with a broader pipeline of new developments. The BM bid was not a single negotiated deal but the result of an auction style process. Also, looking at the $11 Bil paid for Alza. Gruntal reiterated their $27 and $40 short and long term targets on Thursday, and Morningstar has a fair market value of $33. Wondering whether these outfits have any tie in that might induce them to inflate their values. Their numbers are in the $8-11+ Bil range.